I can extract side effects.

Chapter 257 The patent stick is about to move
Sitting in the office, Wei Kang looked at the experimental report in front of him, frowning.

The clinical phase III trial report of the thalassemia gene drug has finally come out.

The data was perfect, and all patients had great success with their first treatment.

Patients in the first clinical phase have received the second treatment, and the hemoglobin in their bodies has remained normal for a long time.

This means that the patient's thalassemia has been completely cured and may not need a third treatment.

There are more than 500 patients in the third phase of Huaxia and Yingguo, and there are also 500 patients in the first and second phases.

As a result, the total number of people participating in the clinical trial exceeded 1000, which fully met the FDA's requirements for rapid application for new drugs.

Sanqing will soon announce the official launch of this drug in Eagle Country.

As for Huaxia, the action should be slower, and it is estimated that it will be able to pass the approval and go public in a month or two.

However, Wei Kang is still a little worried. He wants to ensure that there will be no mistakes before the listing.

Because this new drug launch journey was really smooth, not only the painkiller was successfully launched in the Eagle Country, it was sold at a high price.

The treatment appointments for the new thalassemia drug in major hospitals in Eagle Country have already been scheduled for three months.

Everything looks immaculate and ready to go on the market.

Wei Kang thought for a long time, and dug out the patent information from the computer.

The thalassemia gene drug has registered drug-related patents in both Huaxia and Yingguo, and there is no problem with this.

As for the patent right of CRISPR gene editing technology, the Huaxia Intellectual Property Office awarded it to the research team of the University of California, that is, the team of Nobel Prize winner Dr. Doudna.

The Europa Patent Office has also granted the University of California's patent with this broad claim.

Obviously, the University of California owns the patent ownership of this gene editing technology.

Therefore, Sanqing also contacted the team of the University of California in the process of new drug approval, and obtained the other party's patent license.

For academic researchers, as long as they don't profit from the work, they can use the technology without hindrance.

But for commercial organizations, obtaining a patent license is quite expensive, and an agreement must be reached with the patent owner.

Sanqing has considered this point, and after obtaining the patent license, it has negotiated the price with Dr. Doudna's team.

However, the patent appears to be in trouble in Eagle Country, caught in a protracted patent battle.

The thing is, in 2012, after the University of California team published a paper in the "Science" magazine that the "genetic scissors" CRISPR-Cas9 can precisely cut DNA in a test tube, it has not had time to apply for a patent to the Eagle Country Patent Office.

Another institution caught wind of it, and Zheng Feng's team at the Broad Institute took the lead in realizing the gene editing of this technology in human cells, and immediately applied for a patent.

Although both teams filed patent applications at about the same time, the Broad Institute was the first to be awarded the patent for the CRISPR system for editing eukaryotic cells due to the fast-track application by the Broad Institute.

However, the University of California's patent application for CRISPR-Cas9 to edit all types of cells, including bacteria, plants, animals and humans, has not been approved for a long time, and even faces the consequences of being returned.

The University of California did not give up easily. They have been fighting the Broad Institute to fight for the ownership of the patent.

After the Doudna team won the Nobel Prize, it also established its status as an orthodox inventor.

They have received support from patent offices in countries such as China and Europe, and obtained patent rights.

Only in Eagle Country, the two sides were caught in the quagmire of the patent battle, and it was still unable to reach a conclusion.

The latest news is that the Eagle State Patent Office rejected the application of the University of California and granted the patent rights of CRISPR to the Broad Institute, but the University of California is obviously not convinced and is already holding back its big move.

It is said that they are ready to seek a legal solution to the judgment of the Eagle State Patent Office, especially after obtaining the patent authorization of Huaxia and Europa, they are more confident and are submitting an appeal to the Eagle State Federal Court.

Clearly, the stakes in CRISPR gene-editing technology are enormous, and neither of these two groups will ever give up.

The Doudna team at the University of California has the support of Europa, and behind the Broad Institute is the Eagle Nation interest group.

The two sides are fighting to the death, and it seems that it has been tied at present, and it is difficult to tell the winner in a short time.

Therefore, many commercial organizations that need the patent authorization of this technology are quietly waiting for the final result.

Fortunately, other regions, such as the Huaxia and Europa Patent Offices, have decided on the ownership of patents early on, so for patent authorization in these countries and regions, you can directly contact the University of California team.

But in Eagle Country, the battle is in full swing, and it is temporarily impossible to determine which side to vote for.

What if the patent authorization of one party is obtained, and the other party wins the lawsuit?
Wouldn't it be nothing to fetch water from a bamboo basket?

So for the time being, no one dared to act rashly, and Sanqing was no exception.

We can only take one step at a time. If any party has any objection to this, we can wait for the other party to come to our door.

After all, no one wants to pay two patent licensing fees at the same time.

Wei Kang rubbed the space between his brows, and finally felt relieved.

It should be fine, completely legal and compliant, no issues to be found.

If there is a problem, it is not his problem.

The next day, Sanqing officially announced the launch of the thalassemia gene drug in Eagle Country.

The price is also in line with Sanqing's consistent style, only one word expensive.

However, this did not have much impact on the influx of patients.

Previously, Sanqing had already launched genetic medicines in Eagle Country, such as SMA and Menkes genetic medicines, both priced at US$30.

Although due to technical complexity, the price of thalassemia gene medicine has risen to 50 US dollars.

But compared to Eagle Country's bone marrow transplant fee of 300 million US dollars, this price is already quite friendly.

Instead, Yingguo netizens kept praising Sanqing on the Internet.

Twitter, Facebook, etc., these platforms are full of praises for Sanqing.

"Thank God I can finally be a normal person and not have to go for blood transfusions every week."

"It is said that Huaxia's companies are price butchers, and they are right. Sanqing is a clean stream among pharmaceutical companies, and the charges are very fair."

"I have already made an appointment for treatment with Sanqing Gene Medicine at the hospital. The whole treatment process will last for one or two months, but the price is still affordable. My insurance can reimburse 70% of the cost, and 15 US dollars can be exchanged for a healthy This is the best money I've ever spent."

"The brother upstairs must have a good job, which is really enviable."

"Since Sanqing began to develop gene medicines, I have never seen millions of dollars in sky-high medicines. This is really gratifying for patients around the world."

"You said, if Sanqing becomes the world's number one pharmaceutical company, will we be freed from the hell of high-priced drugs?"

"Very likely, that will be the gospel for all mankind, and we will completely enter heaven."

******
"Hehe, stupid human beings are simply a bunch of idiots. A small favor has bought a lot of people's hearts."

Seeing the praise of Sanqing on the Internet, Saul was so angry that his beard couldn't help shaking.

It's a pity that these exaggerated compliments are ubiquitous on the Internet, anyone can see them as long as they go online, and there is no way to avoid them.

He quickly made a call.

"How is your evidence collection going?"

"It went very well. The hospital intercepted some genetic medicines as evidence, which contained the existence of CRISPR-Cas9 preparations. The evidence is solid enough to file a lawsuit."

"Hehe, don't worry, wait until the treatment of the first batch of patients is over and the payment is completed."

"clear."

"The patent stick in my hand is already ready to move."

Thor couldn't help but let out a strange laugh, his voice extremely comfortable.

He seemed to have seen the scene of Sanqing being wiped out under an iron fist.

Like a delicate and beautiful maiden, torn at the hands of thugs.

Having stayed in this position for a long time, he has an innate, believer-like fanaticism in his bones for destroying any good things.

The more enthusiastic netizens praised Sanqing, the more intense the pleasure brought by destroying it.

(End of this chapter)